Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Eli Lilly has raised its revenue guidance for 2024 ... In its update, Ricks said a new facility at Concord in North Carolina – part of an $18 billion investment programme launched in 2020 ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...